Close Menu

MDxHealth

The company is developing a liquid biopsy test using the methylation markers, and will report preliminary data at an upcoming urological research meeting.

The growth in revenues was driven by a 177 percent increase in the firm's ConfirmMDx prostate cancer test.

The increase in total revenues resulted from the doubling of sales of the company's ConfirmMDx prostate cancer test.

Oncgnostics will use MDxHealth's methylation-specific PCR in the GynTect test for cervical cancer, the fourth such test to use the technology.

NEW YORK (GenomeWeb) – MdxHealth announced today that it has raised €12.3 milllion ($15.4 million) in a private placement. The firm sold 3.4 million shares at €3.60 per share to a group of institutional, qualified and professional investors.

NEW YORK (GenomeWeb News) – MDxHealth reported today that its third quarter revenues increased 78 percent year over year, driven by growth in its prostate cancer molecular diagnostic test, ConfirmMDx.

NEW YORK (GenomeWeb) – In receiving a final local coverage determination (LCD) for its ConfirmMDx prostate cancer test, MDxHealth is the first company to be reimbursed by Medicare contractor Palmetto GBA under a new "coverage with data development" protocol.

NEW YORK (GenomeWeb) – The Centers for Medicare & Medicaid Services finalized a coverage policy to begin reimbursing MDxHealth's ConfirmMDx prostate cancer test effective Nov. 3.

NEW YORK (GenomeWeb) – MDxHealth today reported that its revenues for the first half of 2014 increased 20 percent over the first half of 2013, driven by sales of its ConfirmMDx prostate cancer test.

NEW YORK (GenomeWeb) – Researchers from Johns Hopkins University have published data from an independent validation study in The Journal of Urology reporting that increased methylation of GSTP

Pages

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.